Generic Medicine Info
Erythromycin base: Should be taken on an empty stomach. Best taken on an empty stomach at least 30 min & preferably 2 hr before meals.
Hypersensitivity. Prolonged QT interval, uncorrected hypokalaemia or hypomagnesaemia, clinically significant bradycardia. Concomitant use with astemizole, terfenadine, cisapride, pimozide, tolterodine, mizolastine, amisulpride, ergotamine or dihydroergotamine, lovastatin, simvastatin, Class 1A or III antiarrhythmic agents.
Special Precautions
Patient with risk factors for prolonged cardiac repolarisation, coronary artery disease, myasthenia gravis. Hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Fungal or bacterial superinfection (e.g. C. difficile-associated diarrhoea [CDAD]); myasthenia gravis; infantile hypertrophic pyloric stenosis; hepatotoxicity. Blood and lymphatic system disorders: Eosinophilia. Cardiac disorders: Chest pain, palpitations. Ear and labyrinth disorders: Deafness, tinnitus. Eye disorders: Mitochondrial optic neuropathy. Gastrointestinal disorders: Nausea, vomiting, abdominal pain, diarrhoea, pancreatitis. General disorders and administration site conditions: Fever, malaise. Hepatobiliary disorders: Cholestatic hepatitis, jaundice, hepatic dysfunction, hepatomegaly, hepatic failure, hepatocellular hepatitis. Immune system disorders: Allergic reactions, anaphylaxis. Investigations: Increased liver enzymes. Metabolism and nutrition disorders: Anorexia. Nervous system disorders: Convulsions, vertigo. Psychiatric disorders: Hallucinations, confusion. Renal and urinary disorders: Interstitial nephritis. Skin and subcutaneous tissue disorders: Pruritus, urticaria, exanthema, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme. Topical: burning, peeling, drying, reddening, oiliness and pruritus at the application site. Vascular disorders: Hypotension.
Potentially Fatal: QT prolongation, ventricular arrhythmias including torsades de pointes, pseudomembranous colitis.
Drug Interactions
Increased risk of hypotension with Ca channel blockers that are metabolised by CYP3A4 (e.g. verapamil, amlodipine, diltiazem). May cause a significant increase in the plasma concentration of colchicine. Decreased serum concentration with CYP3A4 inducers (e.g. rifampicin, phenytoin). May decrease the effectiveness of contraceptives. May increase the effect of oral anticoagulants (e.g. warfarin). May increase plasma concentration of benzodiazepines (e.g. midazolam). May increase the pharmacodynamic effects of zopiclone. Increased plasma concentration with cimetidine.
ATC Classification
D10AF02 - erythromycin ; Belongs to the class of topical antiinfective preparations used in the treatment of acne.
J01FA01 - erythromycin ; Belongs to the class of macrolides. Used in the systemic treatment of infections.
S01AA17 - erythromycin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
Disclaimer: This information is independently developed by CIMS based on erythromycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in